• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Archives for GlaxoSmithKline

RTS,S Malaria Vaccine Phase III Trial Results Show Promise, Though Diminished Effectiveness Over Time

April 27, 2015 By Malaria.com Leave a Comment

Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. … [Read more...]

Filed Under: Malaria News Tagged With: GlaxoSmithKline, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI), RTS-S, RTSS Vaccine

GlaxoSmithKline Applies for Approval of RTS,S Malaria Vaccine

July 29, 2014 By Steve Baragona Leave a Comment

A “pretty good” malaria vaccine is on track to be the first to market. It only prevents infection about one-quarter to one-half the time, so it’s not as good as most vaccines. But for a disease like malaria, which kills 600,000 people a year, “pretty good” may be good enough. GlaxoSmithKline has applied for regulatory approval for its RTS,S vaccine. Partial protection A new 18-month study in … [Read more...]

Filed Under: Malaria News Tagged With: GlaxoSmithKline, Malaria Vaccine, RTSS Vaccine

GlaxoSmithKline Seeks to Market RTS,S Malaria Vaccine

October 8, 2013 By Malaria.com Leave a Comment

British drugmaker GlaxoSmithKline is seeking approval to market the world's first malaria vaccine, after trials showed that it significantly cut cases of the disease in children. Results from latest clinical trial of the RTS,S vaccine were unveiled at a conference in Durban, South Africa on Tuesday. It showed that after 18 months of follow-up, the vaccine halved the number of malaria cases … [Read more...]

Filed Under: Malaria News Tagged With: GlaxoSmithKline, Malaria Vaccine, RTSS Vaccine, VOA

Phase III Trial of RTS,S Malaria Candidate Vaccine Reduces Malaria by One Third

November 9, 2012 By Malaria.com Leave a Comment

Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria … [Read more...]

Filed Under: Malaria News Tagged With: Andrew Witty, Bill & Melinda Gates Foundation, Bill Gates, David Kaslow, GlaxoSmithKline, Malaria Vaccine, PATH Malaria Vaccine Initiative (MVI), RTSS Vaccine, Salim Abdulla

GlaxoSmithKline Malaria Vaccine Candidate Results Disappointing

November 9, 2012 By Malaria.com Leave a Comment

The latest clinical trial of the world’s leading malaria vaccine candidate produced disappointing results on Friday. The infants it was given to had only about a third fewer infections than a control group. Three shots of the vaccine, known as RTS, S or Mosquirix and produced by GlaxoSmithKline, gave babies fewer than 12 weeks old 31 percent protection against detectable malaria and 37 percent … [Read more...]

Filed Under: Malaria News Tagged With: GlaxoSmithKline, Malaria Vaccine, Mosquirix, RTS

Malaria Vaccine

May 25, 2012 By Malaria Q&A Leave a Comment

QUESTION Is there a vaccine for malaria? ANSWER No, as of yet there is not a vaccine available for malaria. The most promising vaccine candidate, RTS,S, which has been developed by GlaxoSmithKline, is currently undergoing Phase III trials in Africa. The trial is not due to finish until 2014, so we will have to wait until then to know how effective it is. Preliminary results, published … [Read more...]

Filed Under: Malaria Q&A Tagged With: Africa, GlaxoSmithKline, Malaria Prevention, mortality, Phase III trials, RTSS, vaccine

Malaria Vaccine

May 13, 2012 By Malaria Q&A Leave a Comment

QUESTION What is the shot you get to prevent malaria? ANSWER There is currently no shot available to prevent malaria. The most promising vaccine candidate, called RTS,S and being developed by GlaxoSmithKline, is currently undergoing Phase III trials in children in Africa. Preliminary results have indicated it may prevent up to 50% of malaria cases, though this varies by age group and … [Read more...]

Filed Under: Malaria Q&A Tagged With: GlaxoSmithKline, Phase III clinical trials, RTS, vaccine

Vaccine for Malaria

May 7, 2012 By Malaria Q&A Leave a Comment

QUESTION Is there a vaccine to prevent malaria? ANSWER No, there is not currently a vaccine available to prevent malaria. The best current candidate, the RTS,S vaccine which was developed by GlaxoSmithKline, is currently undergoing Phase III clinical trials in Africa. Although preliminary results showed up to a 50% rate of protection against malaria in some age groups, the trials will not … [Read more...]

Filed Under: Malaria Q&A Tagged With: Africa, GlaxoSmithKline, Phase III trials, prevention, RTS-S, vaccine

Why not create a vaccine for malaria?

March 12, 2012 By Malaria Q&A Leave a Comment

QUESTION Why not create a vaccine for malaria? ANSWER There are many teams of scientists working hard to try to produce a malaria vaccine. In fact, only last year, the preliminary results of a vaccine trial were published. The vaccine, called RTS,S, has been produced by GlaxoSmithKline and is in the midst of Phase III trials in Africa. The preliminary results showed approximately a … [Read more...]

Filed Under: Malaria Q&A Tagged With: Clinical Trials, financial resources, GlaxoSmithKline, Malaria Vaccine Initiative, morbidity, PATH, pharmaceutical companies, RTS, S, severe malaria, vaccine, vaccine testing

Malaria Vaccine Research

March 9, 2012 By Malaria Q&A Leave a Comment

QUESTION Is there any research to produce anti malaria vaccine, if not, why? ANSWER There are many teams of scientists working hard to try to produce a malaria vaccine. In fact, only last year, the preliminary results of a vaccine trial were published. The vaccine, called RTS,S, has been produced by GlaxoSmithKline and is in the midst of Phase III trials in Africa. The preliminary … [Read more...]

Filed Under: Malaria Q&A Tagged With: GlaxoSmithKline, immune response variation, Malaria Control, malaria research, Malaria Vaccine Initiative, PATH, Phase III trial, Plasmodium, RTS, S, strain variation, vaccine

Next Page »

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2023 Malaria.com · Log in